Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cardiovasc Drugs Ther
Autors principals: Judge, Daniel P., Kristen, Arnt V., Grogan, Martha, Maurer, Mathew S., Falk, Rodney H., Hanna, Mazen, Gillmore, Julian, Garg, Pushkal, Vaishnaw, Akshay K., Harrop, Jamie, Powell, Christine, Karsten, Verena, Zhang, Xiaoping, Sweetser, Marianne T., Vest, John, Hawkins, Philip N.
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7242280/
https://ncbi.nlm.nih.gov/pubmed/32062791
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-019-06919-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars